Dr. Lal PathLabs reports unaudited Q3 and nine-month results for December 31, 2025, with an interim dividend of INR 3.5 per share and 4,000 ESOP shares allotted, boosting paid-up capital. Deloitte provides the review certificate.
AI Assistant
Dr Lal Pathlabs Ltd
2026
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.